Dataset v0.2.0 · computed August 27, 2026 · 19 verified provider(s) · cadence: Continuous
GLP-1 Clinical Evidence Library
An index of the trials and labels this site cites, with registry identifiers, so that every clinical claim can be traced.
Medically reviewed by Dr. S. Shuwart, MD · August 27, 2026
What it measures
Trial name, registry ID, population, primary outcome and publication, for each entry with a completed clinical review.
Method
Entries are added only after the primary publication and registry record have been retrieved and reviewed; the evidence pages link here. Full definitions: methodology.
Current results
45 sources cited on 22 medically reviewed page(s).
| Source | Type | Cited on | Page | Reviewed by | Reviewed on |
|---|---|---|---|---|---|
| FDA: Human drug compounding — 503A and 503B | regulator | 503A vs 503B pharmacies: what the difference means for your vial | /guides/503a-vs-503b-pharmacy/ | Dr. S. Shuwart, MD | 2026-08-27 |
| FDA: Registered outsourcing facilities | regulator | 503A vs 503B pharmacies: what the difference means for your vial | /guides/503a-vs-503b-pharmacy/ | Dr. S. Shuwart, MD | 2026-08-27 |
| Drug Quality and Security Act of 2013 | statute | 503A vs 503B pharmacies: what the difference means for your vial | /guides/503a-vs-503b-pharmacy/ | Dr. S. Shuwart, MD | 2026-08-27 |
| FDA: Human drug compounding | regulator | Are compounded GLP-1 medications FDA-approved? No — here is what that means | /guides/are-compounded-glp1-fda-approved/ | Dr. S. Shuwart, MD | 2026-08-27 |
| FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss | regulator | Are compounded GLP-1 medications FDA-approved? No — here is what that means | /guides/are-compounded-glp1-fda-approved/ | Dr. S. Shuwart, MD | 2026-08-27 |
| USP General Chapter <797> Pharmaceutical Compounding — Sterile Preparations | standard | Beyond-use dates for compounded GLP-1 vials | /guides/beyond-use-dates-compounded-glp1/ | Dr. S. Shuwart, MD | 2026-08-27 |
| Zepbound (tirzepatide) prescribing information | label | Brand-name vs compounded GLP-1: what the difference is and what it costs | /guides/brand-vs-compounded-glp1/ | Dr. S. Shuwart, MD | 2026-08-27 |
| Wegovy (semaglutide) prescribing information | label | Brand-name vs compounded GLP-1: what the difference is and what it costs | /guides/brand-vs-compounded-glp1/ | Dr. S. Shuwart, MD | 2026-08-27 |
| Federal Food, Drug, and Cosmetic Act section 503A (valid prescription requirement) | statute | Compounded GLP-1 prescription rules by provider | /guides/compounded-glp1-prescription-rules/ | Dr. S. Shuwart, MD | 2026-08-27 |
| Zepbound and Wegovy prescribing information (warnings and precautions) | label | Compounded GLP-1 safety: what is known, what is not | /guides/compounded-glp1-safety/ | Dr. S. Shuwart, MD | 2026-08-27 |
| FDA Drug Shortages database entry for semaglutide injection | regulator | Compounded semaglutide legal status | /guides/compounded-semaglutide-legal-status/ | Dr. S. Shuwart, MD | 2026-08-27 |
| FDA: Clarification of policies for compounders as national GLP-1 supply begins to stabilize | regulator | Compounded semaglutide legal status | /guides/compounded-semaglutide-legal-status/ | Dr. S. Shuwart, MD | 2026-08-27 |
| FDA: Medications containing semaglutide marketed for type 2 diabetes or weight loss | regulator | Compounded semaglutide legal status | /guides/compounded-semaglutide-legal-status/ | Dr. S. Shuwart, MD | 2026-08-27 |
| FDA Drug Shortages database entry for tirzepatide injection | regulator | Compounded tirzepatide legal status: shortage end, enforcement and personalised compounding | /guides/compounded-tirzepatide-legal-status/ | Dr. S. Shuwart, MD | 2026-08-27 |
| Federal Food, Drug, and Cosmetic Act sections 503A and 503B | statute | Compounded tirzepatide legal status: shortage end, enforcement and personalised compounding | /guides/compounded-tirzepatide-legal-status/ | Dr. S. Shuwart, MD | 2026-08-27 |
| Zepbound and Wegovy prescribing information (composition sections) | label | GLP-1 additives (B12, B6, glycine, niacinamide, L-carnitine): what they are and the evidence | /guides/glp1-additives-b12-glycine-niacinamide/ | Dr. S. Shuwart, MD | 2026-08-27 |
| FDA: Compounding and the FDA — questions and answers | regulator | How online GLP-1 telehealth works, step by step | /guides/how-online-glp1-telehealth-works/ | Dr. S. Shuwart, MD | 2026-08-27 |
| Social Security Act §1860D-2(e)(2)(A) (Part D excluded drugs, incorporating Medicaid's weight-loss exclusion) | statute | Medicare, Medicaid and GLP-1 coverage for weight management | /guides/medicare-medicaid-glp1-coverage/ | Dr. S. Shuwart, MD | 2026-08-27 |
| CMS guidance on Part D coverage of anti-obesity medications for medically accepted indications (2024) | regulator | Medicare, Medicaid and GLP-1 coverage for weight management | /guides/medicare-medicaid-glp1-coverage/ | Dr. S. Shuwart, MD | 2026-08-27 |
| CMS Contract Year 2026 Part D proposed rule and final rule (2024–2025) | regulator | Medicare, Medicaid and GLP-1 coverage for weight management | /guides/medicare-medicaid-glp1-coverage/ | Dr. S. Shuwart, MD | 2026-08-27 |
| Mounjaro (tirzepatide) prescribing information | label | Mounjaro vs compounded tirzepatide | /guides/mounjaro-vs-compounded-tirzepatide/ | Dr. S. Shuwart, MD | 2026-08-27 |
| Ozempic (semaglutide) prescribing information | label | Ozempic vs compounded semaglutide | /guides/ozempic-vs-compounded-semaglutide/ | Dr. S. Shuwart, MD | 2026-08-27 |
| FDA guidance: Compounded drug products that are essentially copies of a commercially available drug product under section 503A | regulator | Personalised compounding: what makes a compounded GLP-1 permissible after the shortage | /guides/personalized-compounding-requirements/ | Dr. S. Shuwart, MD | 2026-08-27 |
| Ozempic and Wegovy prescribing information (description sections) | label | Semaglutide base vs sodium and acetate salts | /guides/semaglutide-base-vs-salt/ | Dr. S. Shuwart, MD | 2026-08-27 |
| Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021 | trial | Semaglutide clinical trials: STEP and SELECT results in plain language | /evidence/semaglutide-clinical-trials/ | Dr. S. Shuwart, MD | 2026-08-27 |
| Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity and type 2 diabetes (STEP 2). Lancet 2021 | trial | Semaglutide clinical trials: STEP and SELECT results in plain language | /evidence/semaglutide-clinical-trials/ | Dr. S. Shuwart, MD | 2026-08-27 |
| Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy (STEP 3). JAMA 2021 | trial | Semaglutide clinical trials: STEP and SELECT results in plain language | /evidence/semaglutide-clinical-trials/ | Dr. S. Shuwart, MD | 2026-08-27 |
| Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA 2021 | trial | Semaglutide clinical trials: STEP and SELECT results in plain language | /evidence/semaglutide-clinical-trials/ | Dr. S. Shuwart, MD | 2026-08-27 |
| Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med 2022 | trial | Semaglutide clinical trials: STEP and SELECT results in plain language | /evidence/semaglutide-clinical-trials/ | Dr. S. Shuwart, MD | 2026-08-27 |
| Rubino DM et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide (STEP 8). JAMA 2022 | trial | Semaglutide clinical trials: STEP and SELECT results in plain language | /evidence/semaglutide-clinical-trials/ | Dr. S. Shuwart, MD | 2026-08-27 |
| Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med 2023 | trial | Semaglutide clinical trials: STEP and SELECT results in plain language | /evidence/semaglutide-clinical-trials/ | Dr. S. Shuwart, MD | 2026-08-27 |
| Wegovy (semaglutide) prescribing information, clinical studies section | label | Semaglutide clinical trials: STEP and SELECT results in plain language | /evidence/semaglutide-clinical-trials/ | Dr. S. Shuwart, MD | 2026-08-27 |
| FDA: Human drug compounding — bulk drug substances | regulator | Tirzepatide base vs salt forms: why it matters and how to ask | /guides/tirzepatide-base-vs-salt/ | Dr. S. Shuwart, MD | 2026-08-27 |
| Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022 | trial | Tirzepatide clinical trials: SURMOUNT and SURPASS results in plain language | /evidence/tirzepatide-clinical-trials/ | Dr. S. Shuwart, MD | 2026-08-27 |
| Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet 2023 | trial | Tirzepatide clinical trials: SURMOUNT and SURPASS results in plain language | /evidence/tirzepatide-clinical-trials/ | Dr. S. Shuwart, MD | 2026-08-27 |
| Wadden TA et al. Tirzepatide after intensive lifestyle intervention (SURMOUNT-3). Nat Med 2023 | trial | Tirzepatide clinical trials: SURMOUNT and SURPASS results in plain language | /evidence/tirzepatide-clinical-trials/ | Dr. S. Shuwart, MD | 2026-08-27 |
| Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA 2024 | trial | Tirzepatide clinical trials: SURMOUNT and SURPASS results in plain language | /evidence/tirzepatide-clinical-trials/ | Dr. S. Shuwart, MD | 2026-08-27 |
| Aronne LJ et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med 2025 | trial | Tirzepatide clinical trials: SURMOUNT and SURPASS results in plain language | /evidence/tirzepatide-clinical-trials/ | Dr. S. Shuwart, MD | 2026-08-27 |
| Malhotra A et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med 2024 | trial | Tirzepatide clinical trials: SURMOUNT and SURPASS results in plain language | /evidence/tirzepatide-clinical-trials/ | Dr. S. Shuwart, MD | 2026-08-27 |
| Zepbound (tirzepatide) prescribing information, clinical studies section | label | Tirzepatide clinical trials: SURMOUNT and SURPASS results in plain language | /evidence/tirzepatide-clinical-trials/ | Dr. S. Shuwart, MD | 2026-08-27 |
| Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med 2021 | trial | Tirzepatide vs semaglutide: the head-to-head evidence | /evidence/tirzepatide-vs-semaglutide/ | Dr. S. Shuwart, MD | 2026-08-27 |
| Jastreboff AM et al. SURMOUNT-1. N Engl J Med 2022 | trial | Tirzepatide vs semaglutide: the head-to-head evidence | /evidence/tirzepatide-vs-semaglutide/ | Dr. S. Shuwart, MD | 2026-08-27 |
| Wilding JPH et al. STEP 1. N Engl J Med 2021 | trial | Tirzepatide vs semaglutide: the head-to-head evidence | /evidence/tirzepatide-vs-semaglutide/ | Dr. S. Shuwart, MD | 2026-08-27 |
| FDA Drug Shortages database | regulator | What happens to compounded GLP-1s when an FDA shortage ends | /guides/when-an-fda-shortage-ends/ | Dr. S. Shuwart, MD | 2026-08-27 |
| FDA guidance: Compounded drug products that are essentially copies of approved drug products under section 503B | regulator | What happens to compounded GLP-1s when an FDA shortage ends | /guides/when-an-fda-shortage-ends/ | Dr. S. Shuwart, MD | 2026-08-27 |
- A source enters the library when the page citing it has been signed by the medical reviewer; the page and the sign-off date are shown for each entry.
Cite and reuse
“Best GLP-1 Telehealth — GLP-1 Clinical Evidence Library, dataset v0.2.0, computed 2026-08-27.” Data: JSON · CSV · licence. Corrections: report an error.